Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide, and in the US one out of three men and women will die from CVD. These statistics are prompting researchers and healthcare professionals to continually explore innovative approaches to not only prevent the development of CVD but also to enhance treatment outcomes. One such groundbreaking field is pharmacogenomics, which focuses on understanding how an individual’s genetic makeup influences their response to drugs. In recent years, pharmacogenomics has emerged as a promising avenue for tailoring cardiovascular disease treatments, optimizing efficacy, minimizing adverse effects, and personalizing medicine for better patient outcomes
Read more
